Loading...
Docoh
Log in Free sign up

Atossa Therapeutics (ATOS)

News

From Benzinga Pro
20 Stocks Moving in Wednesday's Pre-Market Session
8 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Cyren Ltd. (NASDAQ: CYRN) rose 31.1% to $2.32 in pre-market trading after the company entered into an agreement with Content Services Group to sell all equity interests in its legacy secure email gateway business.
Stocks That Hit 52-Week Lows On Wednesday
25 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 215 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
24 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 540 companies set new 52-week lows.
Atossa Genetics Q1 EPS $(0.04), Same YoY
9 May 22
Earnings, News
Atossa Genetics (NASDAQ:ATOS) reported quarterly losses of $(0.04) per share. This is unchanged from the same period last year.
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
62 Biggest Movers From Yesterday
28 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Tenon Medical, Inc. (NASDAQ: TNON) rose 350% to clsoe at $22.50 on Wednesday after the company priced its IPO at $5.00 per share.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Atossa Therapeutics Announces Completion Of Part B Of Clinical Study Of AT-H201
20 Apr 22
Biotech, General
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current

Press releases

From Benzinga Pro
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
2 Jun 22
News, Health Care, Management, Press Releases
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
18 May 22
News, Press Releases
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
9 May 22
Earnings, Press Releases
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with
Atossa Therapeutics to Present at the Q2 Investor Summit Conference
27 Apr 22
Press Releases
SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
20 Apr 22
Health Care, Press Releases, General
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND "LONG HAUL" PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE NEWSWIRE) -- Atossa